Regencell Bioscience Statistics Share Statistics Regencell Bioscience has 494.49M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 494.49M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) 0.07% Shares Floating 18.43M Failed to Deliver (FTD) Shares 38,004 FTD / Avg. Volume 4.21%
Short Selling Information The latest short interest is 1.9M, so 0.38% of the outstanding
shares have been sold short.
Short Interest 1.9M Short % of Shares Out 0.38% Short % of Float 2.06% Short Ratio (days to cover) 6.51
Valuation Ratios The PE ratio is -9.71 and the forward
PE ratio is null.
Regencell Bioscience's PEG ratio is
0.36.
PE Ratio -9.71 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 5.08 P/FCF Ratio -10.42 PEG Ratio 0.36
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Regencell Bioscience.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 41.92,
with a Debt / Equity ratio of 0.01.
Current Ratio 41.92 Quick Ratio 41.92 Debt / Equity 0.01 Debt / EBITDA -0.02 Debt / FCF -0.02 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-358.49K Employee Count 12 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 9553.15% in the
last 52 weeks. The beta is 2.15, so Regencell Bioscience's
price volatility has been higher than the market average.
Beta 2.15 52-Week Price Change 9553.15% 50-Day Moving Average 13.86 200-Day Moving Average 8.23 Relative Strength Index (RSI) 54.67 Average Volume (20 Days) 902,771
Income Statement
Revenue n/a Gross Profit -745.59K Operating Income -4.74M Net Income -4.3M EBITDA -3.62M EBIT -4.36M Earnings Per Share (EPS) -0.01
Full Income Statement Balance Sheet The company has 2.96M in cash and 85.74K in
debt, giving a net cash position of 2.88M.
Cash & Cash Equivalents 2.96M Total Debt 85.74K Net Cash 2.88M Retained Earnings -21.62M Total Assets 8.44M Working Capital 7.92M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -4M
and capital expenditures -5.38K, giving a free cash flow of -4.01M.
Operating Cash Flow -4M Capital Expenditures -5.38K Free Cash Flow -4.01M FCF Per Share -0.01
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields RGC does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for RGC.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 16, 2025. It was a
forward
split with a ratio of 38:1.
Last Split Date Jun 16, 2025 Split Type forward Split Ratio 38:1
Scores Altman Z-Score 20414.37 Piotroski F-Score 2
